GLP-1 RA and Basal Insulin: Individualizing Therapy for Clinical Practice

Title:

GLP-1 RA and Basal Insulin: Individualizing Therapy for Clinical Practice

Topic: Endocrinology
Relevant Terms: Type 2 diabetes; insulin; GLP-1 receptor agonists; combination therapy
Primary Audience: Primary Care Providers, Nurse Practitioners, Physician Assistants
Launch Date: 11-Jul-17
Credits: 1.5 AMA PRA Category 1 Credits
Expiration Date: 25-Jul-18
Curriculum Name: GLP-1 RA and Basal Insulin Combinations: New Options for Treatment Intensification

Learning Objectives

After completing this activity, the participant will demonstrate the ability to:

  1. Implement strategies that reduce barriers to treatment intensification in patients on OADs and/or insulin
  2. Outline the advantages of a pathophysiologic approach to the management of dysglycemia in T2DM
  3. Describe the glucose lowering effects of short- and long-acting GLP-1 receptor agonists
  4. Incorporate fixed-ratio combination GLP-1 RA and basal insulin products in the treatment of patients with T2DM

    Faculty

    Mark E. Molitch, MD
    Martha Leland Sherwin Professor of Endocrinology
    Division of Endocrinology, Metabolism and Molecular Medicine
    Northwestern University Feinberg School of Medicine
    Chicago, IL
    Lyle D. Mitzner, MD
    Assistant Professor of Medicine, Harvard Medical School
    Attending Physician in Endocrinology, Beth Israel Deaconess Medical Center
    Staff Physician, Joslin Diabetes Center
    Boston, MA
    LAUNCH DATE/EXPIRATION DATE
    This activity was launched on July 11, 2017 and will expire on July 25, 2018.
     
    TARGET AUDIENCE
    This activity has been designed to meet the educational needs of primary care providers, NPs, PAs and other health care professionals involved in the care of patients with Type 2 diabetes.

    ACCREDITATION STATEMENT
    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.

    CREDIT DESIGNATION
    Horizon CME designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
     
    HOW TO CLAIM CREDIT
    By reviewing the course content and successfully completing the post-test and evaluation, physicians are entitled to receive 1.5 AMA PRA Category 1 Credits™. Statement of credit will be available to print from your user history page.
     
    • Read the learning objectives and faculty disclosures.
    • Participate in the activity.
    • Complete the post-test and activity evaluation.
    • Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score with an 75% or higher on the post-test to receive credit for this activity.
    • All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
    LEARNER ASSURANCE STATEMENT
    Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
     
    Name of Faculty Reported Financial Relationship
    Lyle Mitzner, MD
    Dr. Mitnzer has served on an Advisory Board for Conversa Health.
    Mark Molitch, MD Dr. Molitch has served on an Advisory Board for Janssen, Novo Nordisk, and he has performed contracted research for Bayer, Novo Nordisk, Novartis, Calibra Bioceuticals, Prolor Biotech, and Chiasma. Dr. Molitch has received funds for consulting from Merck, Pfizer, Novartis, and Chiasma.
     
    OTHER CONTRIBUTORS Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclosed no relevant financial relationships with any ACCME defined commercial interest.

    DISCLOSURE OF UNLABELED USE
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 
     
    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
     
    SUPPORTER ACKNOWLEDGEMENT
    This activity is supported by an educational grant from Sanofi US.       
     
    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
     
    COURSE VIEWING REQUIREMENTS
    Supported Browsers:
    Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8
    Google Chrome 28.0+ for Windows, Mac OS, or Linux
    Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
    Safari 6+ for Mac OSX 10.7 and above

    For video playback, install the latest version of Flash or Quicktime.
    Supported Phones & Tablets:
    Android 4.0.3 and above
    iPhone/iPad with iOS 6.1 or above